Navigation Links
AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
Date:12/18/2009

QUEBEC CITY, Dec. 18 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on oncology and endocrine therapy, today announced the termination of its agreement with sanofi-aventis U.S. ( SNY) dated March 5, 2009 for the development, commercialization and licensing of cetrorelix in benign prostatic hyperplasia (BPH) for the U.S. market, following the Company's announcement last week of the results for its European Phase 3 study for cetrorelix in BPH. Termination of the agreement will be effective January 9, 2010.

Cetrorelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, had been the object of a Phase 3 program in BPH, a non-cancerous enlargement of the prostate which, as announced by the Company last week, did not meet its primary endpoint.

Juergen Engel, Ph.D., AEterna Zentaris President and CEO stated, "The termination of our agreement with sanofi-aventis U.S. was expected in light of last week's announcement. Our clinical development efforts will now be focused on the following late-stage compounds: in oncology, Keryx, our partner and licensee in North America, has just initiated a Phase 3 trial in multiple myeloma with perifosine, our oral PI3K/Akt inhibitor compound. We are also currently evaluating further development plans for AEZS-108, our targeted doxorubicin conjugate, after recent positive Phase 2 results in ovarian and endometrial cancer. In endocrinology, we are in the process of reactivating a Phase 3 trial with our oral ghrelin agonist, AEZS-130, as a diagnostic test for adult growth hormone deficiency."

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on oncology and endocrine therapy, with proven expertise in drug discovery, development and commerc
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
2. AEterna Zentaris Announces Appointment of New Board Member
3. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
4. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
5. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
6. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
7. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
8. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
9. AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency
10. AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer
11. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- , Not for release, publication or distribution ... jurisdiction where to do so would constitute a violation of ... ("Shire" or the "Company") (LSE: SHP, NASDAQ: SHPG ... has held a meeting with representatives of AbbVie. ... agreement or approval of AbbVie. A further update ...
(Date:7/11/2014)... July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. ... (eslicarbazepine acetate) for use as a once-daily adjunctive ... with epilepsy who are not satisfactorily controlled with conventional ... in patients under 18 years of age. ... disorders and according to Epilepsy Canada, it affects 0.6% ...
(Date:7/10/2014)... July 10, 2014 Product and ... very low abundance and are often “lost in ... time-consuming. , Join presenters Dr. Rowel Tobias, Senior ... John Anders, Head of Quality at Nanotherapeutics, Inc., ... that can speed detection and quantitation while achieving ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Unraveling ... closer together. The Archer Family purchased a ... within DNA, but ended up with a lifetime of ... contained within the family members’ DNA genuinely brought the ... decided to search deeper into genetic history and prior ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5
... Cover the Use of Pharsight Software for In-Vitro / ... Correlation Modeling ... Pharsight(R),Corporation (Nasdaq: PHST ), a leading provider ... drug,development, today announced that Jason Chittenden, MS, Director of,Training ...
... (Nasdaq:,INSM), a developer of follow-on biologics and biopharmaceuticals, ... before The NASDAQ Listing,Qualifications Panel (,the Panel") to ... common stock from The NASDAQ Capital Market., ... Market ("NASDAQ") on,June 17, 2008 indicating that the ...
... / b3c newswire /  - Rentschler Biotechnologie, ... Arzneimittel gibt die Inbetriebnahme einer 2.500 Liter ... über neun unabhängige GMP-Produktionslinien mit Arbeitsvolumen von ... die Herstellung von klinischen Prüfmustern und für ...
Cached Biology Technology:Pharsight to Present on IVIVC at Bioequivalence & Bioavailability Strategies Conference 2Pharsight to Present on IVIVC at Bioequivalence & Bioavailability Strategies Conference 3Insmed to Request Hearing Before NASDAQ Panel to Review NASDAQ Staff Determination 2Rentschler Biotechnologie erweitert Kapazitten fr Produktion in Sugetierzellen 2
(Date:7/10/2014)... , July 1, 2014 Smart ... way for convenience and improved security: NXT-ID, Inc. (OTCBB: NXTD), ... GOOG ), Apple Inc. (NASDAQ: AAPL ... Corporation (NYSE: MA) NXT-ID, Inc., (OTCQB: NXTD) a biometric ... to announce that the second series of 30 second spots ...
(Date:7/10/2014)... NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused on the growing ... was interviewed on July 1 st on the Downtown ... Mr. Pereira discusses the company,s next generation smart wallet with ... Wocket™ aims to replace a traditional wallet with a new ... tells Gino he has never heard of the Wocket and ...
(Date:7/10/2014)... , July 7, 2014 Fingerprint Cards, ... major design win (DW). A Chinese Top 5 smartphone OEM ... start of mass production in October 2014.   ... Top 5 smartphone OEM, which has a planned date for ... target sales volume for this phone of 3 million units. ...
Breaking Biology News(10 mins):Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4FPC Wins DW for 1021 Touch Sensor for Flagship Smartphone from Chinese Top 5 Smartphone OEM 2
... -- (Oct. 20, 2011) -- Junrong Zheng,s techniques to see ... young Rice University scientist a highly prestigious Packard Fellowship. ... students will use the five-year grant that comes with the ... the conformation -- the shape and orientation -- of any ...
... Rochelle, NY, October 20, 2011Spas that offer massage therapy ... levels of potentially harmful indoor air pollutants such as ... an article in Environmental Engineering Science , a ... . The article is available free online at ...
... the association for informatics professionals, honors four leaders ... to be presented during AMIA,s Annual Symposium, Oct. ... professionals to the Washington Hilton over the coming ... whose contributions to the health sector have had ...
Cached Biology News:Rice's Zheng wins Packard Fellowship 2Can aromatherapy produce harmful indoor air pollutants? 2AMIA honors informatics professionals who are improving health, changing the world 2AMIA honors informatics professionals who are improving health, changing the world 3
...
Rabbit polyclonal to MCP2 ( Abpromise for all tested applications). entrezGeneID: 6355 SwissProtID: P49873...
Mouse monoclonal antibody raised against a partial recombinant AATK. NCBI Entrez Gene ID = AATK...
... AS-2057 are fully automatic sample injection systems ... of precision. Sampling flexibility is unparalleled with ... automation and combinatorial chemistry. Also available is ... standard rack for 50 2,ml vials. The ...
Biology Products: